

## Isis Pharmaceuticals to Present at Upcoming Investor Conferences

September 3, 2015

CARLSBAD, Calif., Sept. 3, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the following investor conferences:

- 10<sup>th</sup> Annual Wells Fargo Healthcare Conference on Thursday, September 10, 2015 in Boston, MA;
- 2015 Morgan Stanley Global Healthcare Conference on Friday, September 18, 2015 in New York, NY; and
- Leerink Partners Rare Disease Roundtable on Wednesday, September 30, 2015 in New York, NY.



The above listed dates are subject to change. Details on presentation times or changes to presentation dates can be found on the Company's website. Please check [www.isispharm.com](http://www.isispharm.com) for the latest information.

A live webcast of the presentations will be available on the "Investors & Media" section of the Isis website. The replays will be available within 48 hours and will be archived for a limited time.

### **ABOUT ISIS PHARMACEUTICALS, INC.**

Isis is exploiting its leadership position in RNA-targeted technology to discover and develop novel drugs for its product pipeline and for its partners. Isis' broad pipeline consists of 38 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, including neurological disorders, and cancer. Isis' partner, Genzyme, is commercializing Isis' lead product, KYNAMRO<sup>®</sup>, in the United States and other countries for the treatment of patients with homozygous FH. Isis has numerous drugs in Phase 3 development in severe/rare diseases and cardiovascular diseases. These include volanesorsen, a drug Isis is developing and plans to commercialize through its wholly owned subsidiary, Akcea Therapeutics, to treat patients with familial chylomicronemia syndrome and familial partial lipodystrophy; ISIS-TTR<sub>Rx</sub>, a drug Isis is developing with GSK to treat patients with the polyneuropathy and cardiomyopathy forms of TTR amyloidosis; and ISIS-SMN<sub>Rx</sub>, a drug Isis is developing with Biogen to treat infants and children with spinal muscular atrophy, a severe and rare neuromuscular disease. Isis' patents provide strong and extensive protection for its drugs and technology. Additional information about Isis is available at [www.isispharm.com](http://www.isispharm.com).

### **ISIS PHARMACEUTICALS' FORWARD-LOOKING STATEMENT**

This press release includes forward-looking statements regarding Isis Pharmaceuticals' financial position and outlook, Isis' business, and the therapeutic and commercial potential of Isis' technologies and products, including KYNAMRO, volanesorsen, ISIS-SMN<sub>Rx</sub> and ISIS-TTR<sub>Rx</sub>, in development. Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2014, and its most recent quarterly report on Form 10-Q, which are on file with the SEC. Copies of these and other documents are available from the Company.

In this press release, unless the context requires otherwise, "Isis," "Company," "we," "our," and "us" refers to Isis Pharmaceuticals and its subsidiaries.

Isis Pharmaceuticals<sup>®</sup> is a registered trademark of Isis Pharmaceuticals, Inc. Akcea Therapeutics<sup>™</sup> is a trademark of Isis Pharmaceuticals, Inc. KYNAMRO<sup>®</sup> is a registered trademark of Genzyme Corporation.

Logo - <http://photos.prnewswire.com/prnh/20130807/LA60006L.OGO>

To view the original version on PR Newswire, visit: <http://www.prnewswire.com/news-releases/isis-pharmaceuticals-to-present-at-upcoming-investor-conferences-300137302.html>

SOURCE Isis Pharmaceuticals, Inc.

D. Wade Walke, Ph.D., Vice President, Corporate Communications and Investor Relations, 760-603-2741 ; Amy Williford, Ph.D., Associate Director, Corporate Communications, 760-603-2772